Last reviewed · How we verify
Atazanavir/Ritonavir + Famotidine
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption.
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | Atazanavir/Ritonavir + Famotidine |
|---|---|
| Also known as | Reyataz |
| Sponsor | Bristol-Myers Squibb |
| Drug class | HIV protease inhibitor (boosted) + H2-receptor antagonist |
| Target | HIV protease; CYP3A4 (ritonavir); H2 receptor (famotidine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral load. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, significantly increasing atazanavir plasma concentrations and allowing for lower, more convenient dosing. Famotidine, an H2-receptor antagonist, reduces gastric acid production to optimize the pH-dependent absorption of atazanavir in the gastrointestinal tract.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Hyperbilirubinemia (unconjugated)
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
Key clinical trials
- Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection (PHASE4)
- Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir (PHASE1)
- Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |